Companies / Mineralys Therapeutics Inc
Mineralys Therapeutics Inc
Nasdaq: MLYSCIK 1933414RADNOR, PA
Financials
Ownership
88.4M shares outstanding · as of Aug 3, 2026
Ownership
| Insiders | 16.60% | 14,671,288 |
| 10%+ / strategic | 10.33% | 9,131,166 |
| Institutions | 82.49% | 72,929,881 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 15
View all →| Insider | % of shares | Shares |
|---|---|---|
Slingsby Brian TaylorDirector · 10% owner | 8.95% | 7,910,038 |
RA Capital Management, L.P.Director | 6.59% | 5,825,521 |
Congleton JonCEOChief Executive Officer · Director | 0.88% | 780,051 |
Rodman David MalcomChief Medical Officer | 0.09% | 76,140 |
Levy Adam ScottCFO and Secretary | 0.05% | 48,538 |
Akkaraju SrinivasDirector · 10% owner | <0.01% | 6,200 |
DiRocco DerekDirector | <0.01% | 6,200 |
Gold Alexander MDirector | <0.01% | 6,200 |
Karydas DaphneDirector | <0.01% | 6,200 |
Sblendorio GlennDirector | <0.01% | 6,200 |
Institutional holders 227
View all →| Holder | Value | % of shares |
|---|---|---|
| $286.83M | 8.94% | |
| $213.06M | 6.64% | |
| $208.40M | 8.70% | |
| $183.54M | 5.72% | |
| $158.83M | 6.66% | |
| $121.68M | 3.79% | |
| $111.74M | 4.68% | |
| $100.62M | 3.14% | |
| $64.91M | 2.02% | |
| $60.47M | 2.52% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q3 2025 as of | Farallon Capital Management LLC 13F manager | New | Common Stock | $63.44M | +1.7M | 1,673,053 1.89% of shares | high |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common Stock | $42.07M | +1.6M +36.03% | 5,887,038 6.66% of shares | medium |
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | Trim | Common Stock | $-32.31M | -1.2M -98.36% | 19,848 0.02% of shares | medium |
| Q4 2025 as of | Farallon Capital Management LLC 13F manager | Trim | Common Stock | $-30.84M | -850K -50.79% | 823,296 0.93% of shares | medium |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Add | Common Stock | $29.05M | +1.1M +109.39% | 2,052,900 2.32% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common Stock | $25.81M | +957K +30.04% | 4,141,636 4.68% of shares | medium |
| Q2 2026 as of | Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 13F manager | Exit | Common Stock | $-23.92M | -659K -100.00% | — | medium |
| Q3 2025 as of | Barclays PLC 13F manager | Add | Common Stock | $19.34M | +510K +354.41% | 653,830 0.74% of shares | medium |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Catalys Pacific Fund, LP | Passive13G/A | — |
| BlackRock, Inc. | Passive13G | — |
| Fmr LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| MLYS | Common Stock | 603170101 |